Showing 1641-1650 of 2656 results for "".
- China’s First IGF-1R Monoclonal Antibody Approved, Innovent Biologics Announceshttps://modernod.com/news/chinas-first-igf-1r-monoclonal-antibody-approved-innovent-biologics-announces/2482701/Innovent Biologics announced China’s approval of SYCUME® for thyroid eye disease (TED) earlier this week. SYCUME® is China’s first monoclonal antibody therapeutic option for TED and only the second available globally – marking the first new treatment
- Eyenovia's Late-Stage Pediatric Myopia Treatment Fails to Meet Primary Endpointhttps://modernod.com/news/eyenovias-late-stage-pediatric-myopia-treatment-fails-to-meet-primary-endpoint/2482544/Eyenovia announced that its phase 3 CHAPERONE study failed to meet its primary endpoint. The study was investigating Eyenovia’s proprietary drug-device combination, using low-dose atropine dispensed through the company's Optejet platform, as a potential treatment for pediatric
- J-Code for Glaukos’ iDose TR Becomes Activehttps://modernod.com/news/cms-j-code-for-glaukos-idose-tr-becomes-active/2482340/Glaukos announced that the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for the company’s iDose TR is effective. The J-code provides patient access and streamlines the coverage and payment process as Glaukos advances its commercial launch of the treatment.<
- NurExone’s Exosome-Based Exopten Therapy Studied to Treat Glaucomahttps://modernod.com/news/nurexones-exosome-based-exopten-therapy-studied-to-treat-glaucoma/2482339/NurExone Biologic announced a preclinical study to explore the potential of one of the company’s exosome-based therapies, Exopten, in regenerating damaged optic nerves. The study is NurExone Biologic’s latest step in expanding potential clinical indications for its exosome-loaded
- FDA Approves First Interchangeable Biosimilars to Eyleahttps://modernod.com/news/fda-approves-first-interchangeable-biosimilars-to-eylea/2482286/The FDA has approved Biocon’s Yesafili (aflibercept-jbvf) and Samsung Bioepis and Biogen’s Opuviz (aflibercept-yszy) as the first interchangeable biosimilars to Eylea (aflibercept). Yesafili and Opuviz are used to treat wet age-related macular degeneratio
- Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovationhttps://modernod.com/news/regeneron-backs-500-million-venture-capital-fund-for-biotechnology-innovation/2482234/Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, MD, and Michael Aberman, M
- TheiaNova Selected as Finalist at Eyecelerator for Keratoconus Therapy; Launches Capital Raise for Clinical Trialshttps://modernod.com/news/theianova-selected-as-finalist-at-eyecelerator-for-keratoconus-therapy-launches-capital-raise-for-clinical-trials/2482215/New Zealand-based TheiaNova has delivered the company’s pitch as a finalist in the renowned Eyecelerator event in Boston. At the Eyecelerator event, where TheiaNova participated as a finalist, CEO Carissa Fonseca announced the company’s efforts to raise $10 million 
- Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseaseshttps://modernod.com/news/azura-ophthalmics-to-present-new-data-supporting-the-potential-of-azr-md-001-to-be-the-first-ophthalmic-keratolytic-for-ocular-surface-diseases/2482185/Azura Ophthalmics announced multiple presentations highlighting positive efficacy and safety data from phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in meibomian gland dysfunction (MGD). This includes new, long-term data at ASCRS of the company’s lead drug candidat
- Mice Sent to Space on SpaceX Rocket as Part of Oculogenex Gene Therapy Studyhttps://modernod.com/news/gene-therapy-company-oculogenex-set-to-launch-on-spacex-crs-30-today/2482175/Today’s scheduled launch of NASA’s SpaceX CRS-30 mission will carry more than 40 science payloads to the International Space Station for a new round of microgravity research. SpaceX CRS-30 is scheduled to launch today at 4:55 ET. The mission will include Oculogene
- SDC Transitions its Ophthalmic Biometric Division to Ora Inc.https://modernod.com/news/sdc-transitions-its-ophthalmic-biometric-division-to-ora-inc/2482149/Statistics & Data Corporation (SDC) has decided to transition its ophthalmic biometric division to its partner Ora Inc. Since 2005, SDC’s partnership and common ownership with Ora has provided clinical trial services in ophthalmology, while allowing S